Sodium cromoglicate is a mast cell stabiliser which inhibits the release of histamine after exposure to specific antigens. Sodium cromoglicate is typically used as 2% w/v eye drops for the treatment of allergic conjunctivitis, but is also available in oral form for the treatment of food allergy and aerosol for the treatment of asthma. It is poorly absorbed, thus any exposure of the fetus following use during pregnancy is expected to be low.
The available data do not suggest an increased risk of congenital malformation following in utero exposure to sodium cromoglicate. Other pregnancy outcomes have not been studied.
Exposure to sodium cromoglicate at any stage of pregnancy would not usually be regarded as medical grounds for termination of pregnancy or any additional fetal monitoring. However, other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.
This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.
If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.
If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.